logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Gilead Sciences Inc.

Gilead Sciences Inc. (GILD)

Follow

Details

Wall

Profile


Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors.

Issuer Information

Exchange: NASDAQ
Market Cap: 85694490248
CEO: John C. Martin
Employees: 5000
Issuer Type: CS
Auditor: Ernst & Young LLP
Last Audit: UQ
CIK: 882095
Sector: Healthcare
Industry: Biotechnology
Sub-Industry: Biotechnology
NAICS: Biological Product (except Diagnostic) Manufacturin (325414)
SIC: 2836
Last earning call url:
Slideshare slide url:

Contact Information

Main phone: +1 650 574-3000
Address: 333 Lakeside Drive
Address 2:
State: CA
City / Town: Foster City
Country: USA
Postal Code: 94404
Fax:

Videos

No public videos available.

Blog

No Result Found.

News

As I have mentioned over the last few weeks, the tide has started to go out, the market leadership was getting narrower, the advance decline line was deteriorating, and the…
Will Rogers was adored in his era as both an actor and as a humorist. Not surprisingly, because of his common sense, or “horse sense,” he was also known as…
Could it really be true that 80% of Success is Showing Up? This is the third in this series on challenging this myth. In the first two pieces, we found…
Stock in TG Therapeutics (TGTX) popped in Wednesday trading, seeing shares bounce 9.11%. Driving the gains appears to be the favorable deal secured by rival Infinity (INFI) with AbbVie (ABBV)…
For over four decades, Guild Investment Management and its founder Monty Guild have deployed a proven investing strategy, scanning for opportunities in both the U.S. and international markets. The key…
In the U.S. alone, some 3.2 million people have chronic hepatitis C virus. Between 75% and 85% of people infected with hepatitis C virus develop chronic infection. According to data…
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other…
Aging baby boomers face increased cancer risk, and growing numbers of obese and overweight Americans face metabolic disorders that could lead to cardiovascular disease. Debjit Chattopadhyay of ROTH Capital Partners…
Gilead Sciences Inc. (GILD) posted Q2 2014 earnings of $2.36 a share, easily beating the consensus estimate by 58 cents.Sales came in at $6.53 billion, topping earlier estimate by 12%.…
If investors were as practical with their investment portfolio as they are with managing a garden, they might make a lot more money! There are so many analogies between managing…

Trending

Social Mentions about your company in the last seven days
US Banking News
24 Oct 14 15:18:33
Gilead Sciences Hits New 12-Month High at $111.47 $GILD http://t.co/Sos05wG8jC
Alex Beatty
24 Oct 14 15:08:37
RT @jonathanrockoff: A chart from @MarkSchoenebaum showing just how successful Sovaldi's launch has been. $GILD #hepatitisC http://t.co/W2I…
Stockaholics
24 Oct 14 15:08:33
Our Penny Stock Alerts Gained 371% In 2 weeks! Sign Up For Free Text Alerts For Our New Pick: http://t.co/Wsu24zYrur $GILD $NWSA $EBAY
Pzaa...Guy
24 Oct 14 15:04:11
$GILD - Gilead Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/SFlFQRc8tx
alex serri
24 Oct 14 15:04:11
$GILD - Gilead Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/mXnvO1e1vt
scottidiego
24 Oct 14 15:04:07
$GILD - Gilead Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/niWLiVAYCL
NASDAQ
24 Oct 14 15:04:02
$GILD - Gilead Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/2UwZgXOdxX
MAISA
24 Oct 14 15:00:08
$GILD newest HIV treatments, Stribild, was approved 2yrs ago, and prescriptions for the drug suggest it might score $267M in quarterly sales
MAISA
24 Oct 14 14:59:22
$GILD made its bones selling therapies for HIV, and products including Atripla, Truvada and Viread remain key to $GILD
MAISA
24 Oct 14 14:58:57
$GILD No drug has ever had a bigger launch than Gilead's hepatitis C pill Sovaldi, which rang up $5.75 billion in sales during 1stH2014
MAISA
24 Oct 14 14:58:32
$GILD Gilead will report $6 billion in revenue, compared with $2.8 billion reported in the same quarter a year earlier
4-traders.com
24 Oct 14 14:50:03
Gilead Sciences : Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/CfpTeD6228 $GILD $MLMAD
MAISA
24 Oct 14 14:49:12
The SMART investors will layout $RGLS Phase 1 data TO COMPARE Phase 1 data from $GILD $IDIX $MRK $ENTA $ABBV
MAISA
24 Oct 14 14:47:24
$RGLS the average IQ retail investors tend to COMPARE $RGLS Phase 1 data vs. Phase 3 data from $GILD (not $IDIX) $MRK $ENTA $ABBV
Joaquín Primo
24 Oct 14 14:42:38
RT @HenryEChang: $JNJ hopes to 'remain competitive in the #HCV category' - Olysio's market share is shrinking fast. #Harvoni $GILD http://t…
MAISA
24 Oct 14 14:41:59
$RGLS if u compare $RGLS Phase 1 data vs. Phase 3 data from $GILD $IDIX $MRK $ENTA $ABBV = then it is not fair APPLE vs. ORANGE
MAISA
24 Oct 14 14:41:36
if u compare $RGLS Phase 1 data vs. all Phase 1 data from $GILD $IDIX $MRK $ENTA $ABBV - $RGLS is the BEST among those companies
MAISA
24 Oct 14 14:41:20
$RGLS Phase 1 data vs. Phase 1 data from $GILD $IDIX $MRK $ENTA $ABBV = then that is a fair comparison!
MAISA
24 Oct 14 14:40:54
@fit4life64 if u compare $RGLS Phase 1 data vs. Phase 3 data from $GILD $IDIX $MRK $ENTA $ABBV = then it is not fair APPLE vs. ORANGE
MAISA
24 Oct 14 14:39:59
@fit4life64 $RGLS Phase 1 data vs. Phase 1 data from $GILD $IDIX $MRK $ENTA $ABBV = that is a fair comparison!
MAISA
24 Oct 14 14:38:53
@fit4life64 if u compare $RGLS Phase 1 data vs. all Phase 1 data from $GILD $IDIX $MRK $ENTA $ABBV - $RGLS is the BEST among those companies
Bo Czernyk
24 Oct 14 14:35:20
Been > $GILD Sov/IFN/RBV discontinues than many realize. This will influence Payers as $ABBV rolls out. unfairly, # is skewed b/c of IFN/RBV
Despicable Draghi ™
24 Oct 14 14:29:59
@CthruHD $GILD - HIGH $HCN - HIGH $IRM - HIGH $KIM - HIGH $LEG - HIGH $LOW - HIGH $MCK - HIGH $MCO - HIGH $MMM - HIGH $NAVI - HIGH $NU -HIGH
Bo Czernyk
24 Oct 14 14:23:32
.@biotechnicality @JasonCRG @Colavito00 When $ABBV Rx out at 25% < $GILD Harv & Harv Rx delayed by PBC, sure opinion of ABBV will change!
Jack Wang
24 Oct 14 14:22:55
#Gilead $GILD #Harvoni, priced $94k for 12-wk #HepatitisC regime, launched w/ a big bang-first wk new Rx at 2k+ up7%wow #Biotech #Heathcare
Marco Di Dionisio
24 Oct 14 14:13:53
Longs cost basis $CLDX ($15.58) $GE ($26.91) $GILD ($100.26) $JNJ ($83.82) $KO ($37.29) $MU ($27.90) $SWKS ($51.75) $TWTR ($52.12) $V ($177)
Marco Di Dionisio
24 Oct 14 14:10:53
Closed the week with these longs: $CLDX $GE $GILD $JNJ $KO $MU $SWKS $TWTR $V
Jack Wang
24 Oct 14 14:01:55
#Gilead $GILD #Biotech slated to report #earnings Oct 28-all eyes on #HepC #Sovaldi Rx & #Harvoni guidance #bullish http://t.co/ekGgPPXMRZ
Pzaa...Guy
24 Oct 14 13:57:07
$GILD - Gilead Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/NQXprNxl5s
alex serri
24 Oct 14 13:57:07
$GILD - Gilead Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/nMhX0E45Gx
scottidiego
24 Oct 14 13:57:03
$GILD - Gilead Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/HGzGbRNbeb
NASDAQ
24 Oct 14 13:57:02
$GILD - Gilead Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/NPF9vts297
Xetsu
24 Oct 14 13:54:45
$FB new highs afterhours. $YHOO $GILD $BABA where the stocks this week
PHARMD
24 Oct 14 13:47:55
Long $gild $twtr into earnings next week.
4-traders.com
24 Oct 14 13:45:06
Gilead Sciences : Watchers Looking for Commentary on New Drug's Launch -- Earnings Preview http://t.co/6WPENbeDgd $GILD $MLMAD
Traderific
24 Oct 14 13:33:43
SHORT $AMZN 287.06, BUY $EMC 28.17, SELL $GILD 110.71, BUY $JNJ 103.13. More stock tips & details at: http://t.co/dbnFjvTVZP
Henry E. Chang
24 Oct 14 13:29:47
$JNJ hopes to 'remain competitive in the #HCV category' - Olysio's market share is shrinking fast. #Harvoni $GILD http://t.co/QNHxLi3bjX
Becky Hiu
24 Oct 14 13:24:19
$GILD also all timers today
Tyler Marshall
24 Oct 14 13:19:58
@t_nathan95 Took 30% off my $GILD investment today at 110/share simply because I'm up huge in 8 months.
Investors Hangout
24 Oct 14 13:13:18
$EXK Volume Click Here: http://t.co/hVUYhSfVCa Also See: $NSPH $GILD $AEP $AUY ~
Naveen Kumar
24 Oct 14 13:11:35
Harvoni scripts came in strung huh? $GILD
John Anderson
24 Oct 14 13:10:22
$AAPL Very nice! $GILD excellent a nice way to end it
BNK Invest
24 Oct 14 13:09:17
Video: Friday's ETF with Unusual Volume: $BBH $GILD $CELG $BMRN $NPSP #stocks http://t.co/hjeHCmnmJ4
John Earl Burnett
24 Oct 14 13:07:37
Been Awhile…Outpreform List: $AAPL $TRN $DIS $PCLN $OSIS $MNST $BWA $CERN $SU $GOOGL $TWTR $GILD $LOCO $MTRN (cont) http://t.co/39oNaw1pvf
PBA Investment Club
24 Oct 14 13:06:31
At the close our holdings finish +0.33%, overall unrealized gain of 3.11% $GILD leading gains +3.31% #sailfishinestments
Boris
24 Oct 14 13:04:24
RT @OMaxInvestments: $GILD Near-Term minimum target is $112. Breakout target is $116. http://t.co/bWiSe4yh52
12Stocks.com
24 Oct 14 13:00:46
S&P500 #Stocks Trend $EW $FLIR $AVY $VRSN $DAL $GILD $MJN $PG $NUE $STX $EXC $CELG $MCO $CRM $MMM $FE $AEP @ http://t.co/RPeaHBZz9y
12Stocks.com
24 Oct 14 13:00:24
S&P500 #Stocks Performance $EW $KLAC $FLIR $AVY $STT $VRSN $DAL $GILD $MJN $PG $LLY $NUE $PVH $STX $EXC more@ http://t.co/RPeaHBZz9y
12Stocks.com
24 Oct 14 13:00:07
Nasdaq100 #Stocks Trend $GILD $STX $CELG $YHOO $CA $ORLY $ALXN $CERN $CHKP $GRMN $LBTYA $REGN $FISV $PCAR $ILMN @ http://t.co/YdSIjG11yN
12Stocks.com
24 Oct 14 12:59:49
Nasdaq100 #Stocks Performance $KLAC $MXIM $GILD $STX $VOD $CELG $CTRX $BIDU $CTXS $MSFT $YHOO $CA $ORLY more@ http://t.co/YdSIjG11yN

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.